Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05238376
Other study ID # Pro00110028
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 2, 2022
Est. completion date June 2025

Study information

Verified date April 2024
Source Duke University
Contact Lauren Hill, BS
Phone 919-668-2369
Email lauren.bohannon@duke.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this project is to investigate the effects of 12 weeks of high-intensity interval training (HIIT) and resistance training on several domains of health including physical function, cognitive function, mental health, and quality of life in patients who have undergone hematopoietic stem cell transplant (HCT). In addition, the project will determine the effects of 12 weeks of HIIT and resistance training on physical function, caregiver strain, mental health, and caregiver confidence in individuals who are providing care for patients undergoing HCT.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date June 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Patient Inclusion Criteria: 1. =18 years old 2. English speaking 3. Within 90 ± 30 days post allogenic HCT Caregiver Inclusion Criteria: 1. =18 years old 2. English speaking 3. Providing post-discharge care for the patient who has undergone HCT Patient and Caregiver Exclusion Criteria: 1. Have an absolute contraindication to exercise including a recent acute cardiac event (<6 months), unstable angina, uncontrolled dysthymias causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis, suspects or known dissecting aneurism, or coronary artery disease. 2. In addition to these absolute contraindications, the patient and caregiver will complete cardiopulmonary exercise testing (CPET) where the heart rate and heart rhythm will be monitored via a 12-lead ECG before, during, and after the test. The results from the CPET will be reviewed by a physician before the subject is cleared to participate in the HIIT and resistance training program. If the participant is not cleared by the physician following the CPET, then the patient and his or her caregiver will not be eligible to participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise training
12 weeks of high intensity interval training (HIIT) (3x/week) and resistance training (2x/week)

Locations

Country Name City State
United States Duke Adult Blood and Marrow Transplant Clinic Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adherence to prescribed exercise program, as measured by number of total sessions completed 12 weeks
Primary Compliance to prescribed HIIT sessions, as measured by total session time (in minutes) 12 weeks
Primary Compliance to prescribed HIIT sessions, as measured by number of intervals completed 12 weeks
Primary Compliance to prescribed HIIT sessions, as measured by number/percentage of intervals meeting target heart rates 12 weeks
Primary Compliance to prescribed resistance sessions, as measured by number of sets completed 12 weeks
Primary Compliance to prescribed resistance sessions, as measured by number of repetitions completed 12 weeks
Secondary Change in physical function/activity, as measured by SPPB All the task points are added which make the SPPB score. The cut-point for the SPPB is a score of 10. The cumulative and sections scores are assessed individually and comprehensively. This assessment score will be used as a tool for evaluating lower extremity functioning in older persons. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in physical function/activity, as measured by 6-minute walk test The baseline for each patient is made through an algorithm that factors the patients age and gender. The patient's score is compared to what a person that is the patient's same age and gender would get. This comparison is then used as a tool to assess aerobic capacity or endurance. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in physical function/activity, as measured by 30-second sit-to-stand Subjects will sit in a chair with their arms crossed over their chest and rise to a standing position, then return to seated position. They will repeat this as many times as they can in 30 seconds. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in physical function/activity, as measured by grip strength The hand grip is an indicator of upper body strength and has been found to be a good predictor of future functional limitations and disabilities. The hand grip score is determined based on how quickly the participant can squeeze the hand dynamometer. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in physical function/activity, as measured by Fried Frailty The scores of all of the sections are added and if the patient has a score greater or equal to three this assessment deems that the patients is frail. If the patient has a score between 1-2 the patient is deemed pre-frail. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in physical function/activity, as measured by PROMIS Physical Function The questions are asked as interval format with "0-Never" through "5-Always." Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in physical function/activity, as measured by bioelectrical impedance (BIA) Participants will have body composition assessed by bioelectrical impedance spectroscopy (BIS) via a bioimpedance analysis (BIA) device. BIA equipment does not measure muscle mass directly, but instead derives an estimate of muscle mass based on whole-body electrical conductivity. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in physical function/activity, as measured by CPET Exercise capacity will be assessed using a symptom-limited Cardiopulmonary Exercise Test (CPET) on a cycle ergometer or for a six-minute step test with expired gas analysis to determine VO2peak, according to guidelines for clinical populations (Jones et al., 2012). All CPET data will be recorded as the highest 30-second value elicited during the CPET. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in physical function/activity, as measured by Intramuscular Adipose Tissue (IMAT) Longitudinal and transverse ultrasound images of the m. rectus femoris, vastus lateralis, m. intercostalis / m. pectoralis, (head) m. temporalis, and/or (head) styloglossus. Complex grayscale analysis of the images is used to calculate the IMAT. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in physical function/activity, as measured by Intramuscular Glycogen Content (IMGC) Longitudinal and transverse ultrasound images of the m. rectus femoris, vastus lateralis, m. intercostalis / m. pectoralis, (head) m. temporalis, and/or (head) styloglossus. Complex grayscale analysis of the images is used to calculate the IMGC. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in physical function/activity, as measured by muscle thickness Longitudinal and transverse ultrasound images of the m. rectus femoris, vastus lateralis, m. intercostalis / m. pectoralis, (head) m. temporalis, and/or (head) styloglossus, using greyscale analyses. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in physical function/activity, as measured by muscle area Longitudinal and transverse ultrasound images of the m. rectus femoris, vastus lateralis, m. intercostalis / m. pectoralis, (head) m. temporalis, and/or (head) styloglossus, using greyscale analyses. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in physical function/activity, as measured by subcutaneous fat layer thickness Longitudinal and transverse ultrasound images of the m. rectus femoris, vastus lateralis, m. intercostalis / m. pectoralis, (head) m. temporalis, and/or (head) styloglossus, using greyscale analyses. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in cognitive function, as measured by Montreal Cognitive Assessment (MOCA) This administered assessment is subdivided into visuospatial/executive (5pts), naming (3pts), memory (no points), attention(5pts), language(3pts), abstraction(2pts), delayed recall(5pts), and orientation(6pts). All the subdivided sections have as many questions as they have points. For analysis, the cut point is if the patient has less than 26 points. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in cognitive function, as measured by PROMIS Cognitive Function The questions are asked as interval format with "0-Never" through "5-Always." Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in cognitive function, as measured by RBANS RBANS evaluation produces five index scores as well as a total summary score, and total scaled score. Scores range from 40 to 160, with higher scores indicating better performance (Smith et al., 2014). The scaled score classifies neuropsychological performance as: extremely low (69 and below), borderline (70-79), low average (80-89), average (90-109), high average (110-119), superior (120-129), and very superior (130 and above) (Batty et al., 2016; Randolph et al., 1998). Baseline, Post-intervention (week 12), 1 Year
Secondary Change in cognitive function, as measured by Trail making test Trail Making Test parts A and B (TMT-A and -B) will be used for identification of cognitively impairment. Total time to completion will be used as outcome variable for both parts (ranging from 0 to 300 seconds, with higher scores indicating worse performance (Smith et al., 2014). An adjusted mean T-score also will be calculated ranging from 0 to 100 (mean score 50, higher score indicating better performance). The T-score can be adjusted for age, sex, education and ethnicity. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in cognitive function, as measured by Brief Cope Scores are presented for three overarching coping styles as average scores (sum of item scores divided by number of items), indicating the degree to which the respondent has been engaging in that coping style. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in mental health, as measured by PHQ-9 The PHQ-9 consists of 9 items, each of which is scored 0 to 3, giving a 0 to 27 severity score Baseline, Post-intervention (week 12), 1 Year
Secondary Change in mental health, as measured by PC-PTSD/PCL-5 PC-PTSD is a 5 item screen to identify patients with probable PTSD. If the patient screens positive, they then take the PCL-5. The PCL-5 is a 20 item screen to assess symptoms of PTSD. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in mental health, as measured by PROMIS Depression The questions are asked as interval format with "0-Never" through "5-Always." Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in mental health, as measured by PROMIS Anxiety The questions are asked as interval format with "0-Never" through "5-Always." Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in diet/nutrition, as measured by Perioperative Nutrition Screen (PONS) PONS analyzes BMI, weight loss, and food intake to screen for preoperative nutrition risk Baseline, Post-intervention (week 12), 1 Year
Secondary Change in diet/nutrition, as measured by PG-SGA/Clinician SGA Scores for each section can range from 0-4 depending on severity and nutritional impact. The sum of all scores provides the Total PG-SGA score, which can be used to indicate the need for intervention (Bauer et al., 2002) Baseline, Post-intervention (week 12), 1 Year
Secondary Change in diet/nutrition, as measured by ASA-24 ASA-24 is a self-administered 24-hour diet recall Baseline, Post-intervention (week 12), 1 Year
Secondary Change in diet/nutrition, as measured by Food Security Participants will be given the USDA food security survey to review their food securities or insecurities. This is a 10 item survey. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in social support, as measured by PROMIS Emotional Support The questions are asked as interval format with "0-Never" through "5-Always." Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in social support, as measured by PROMIS Social Isolation The questions are asked as interval format with "0-Never" through "5-Always." Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in social support, as measured by Lorig Self Efficacy The Self-Efficacy to Manage Chronic Disease Scale is made up of 6-items on a visual analog scale, ranging from 1 (not at all confident) to 10 (totally confident). Baseline, Post-intervention (week 12), 1 Year
Secondary Change in social support, as measured by CFC-14 CFC-14 is a 14 item questionnaire to assess a patient's consideration of immediate and consideration of future consequences Baseline, Post-intervention (week 12), 1 Year
Secondary Change in social support, as measured by Brief Resilience Scale BRS assesses the patient's ability to recover from stress. The possible score range on the BRS is from 1 (low resilience) to 5 (high resilience). Baseline, Post-intervention (week 12), 1 Year
Secondary Change in caregiver support, as measured by Caregiver Strain index Tool to assess strain on long-term caregivers Baseline, Post-intervention (week 12), 1 Year
Secondary Change in caregiver support, as measured by Preparedness for Caregiving assessment Items are scored by calculating the mean of all items with a range of 0-4. The higher the score, the more prepared the caregiver feels to give care. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in caregiver support, as measured by FACT-GP 21 item assessment scored on a 5-point Likert scale Baseline, Post-intervention (week 12), 1 Year
Secondary Change in caregiver support, as measured by PHQ-2 The PHQ-9 consists of 2 items, each of which is scored 0 to 3, giving a 0 to 6 severity score Baseline, Post-intervention (week 12), 1 Year
Secondary Change in caregiver support, as measured by PCL-5 The PCL-5 is a 20 item screen to assess symptoms of PTSD. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in caregiver support, as measured by Ego Resiliency 14 item survey scored from 0-56, where a higher score indicates higher level of resiliency Baseline, Post-intervention (week 12), 1 Year
Secondary Change in caregiver support, as measured by PROMIS Depression The questions are asked as interval format with "0-Never" through "5-Always." Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in caregiver support, as measured by PROMIS Anxiety The questions are asked as interval format with "0-Never" through "5-Always." Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in caregiver support, as measured by PROMIS Emotional Support The questions are asked as interval format with "0-Never" through "5-Always." Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in caregiver support, as measured by PROMIS Social Isolation The questions are asked as interval format with "0-Never" through "5-Always." Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population. Baseline, Post-intervention (week 12), 1 Year
Secondary Change in microbiota diversity, as measured by skin swabs Skin swab samples batch sequenced and microbiome analyzed Baseline, Post-intervention (week 12), 1 Year
Secondary Change in microbiota diversity, as measured by stool samples Changes in stool samples as measured by 16s rRNA sequencing Baseline, Post-intervention (week 12), 1 Year
Secondary Change in biomarkers of inflammation and frailty, as measured by blood plasma samples Assays evaluating angiogenic, stromal, and inflammatory markers and markers of aging (the Pepper Panel) are used to assess inflammation and frailty Baseline, Post-intervention (week 12), 1 Year
Secondary Overall survival, as measured by medical record review 1 year
Secondary Disease-free survival, as measured by medical record review 1 year
Secondary Rate of bacterial infection, as measured by medical record review 1 year
Secondary Rate of fungal infection, as measured by medical record review 1 year
Secondary Rate of viral infection, as measured by medical record review 1 year
Secondary Rate of overall infection, as measured by medical record review 1 year
Secondary Rate of hospital admission, as measured by medical record review 1 year
Secondary Rate of intensive care unit admission, as measured by medical record review 1 year
Secondary Hospital length of stay, as measured by medical record review 1 year
Secondary Intensive care unit length of stay, as measured by medical record review 1 year
Secondary Number of patients with grade 2+ graft-versus-host disease, as measured by medical record review 1 year
Secondary Transplant length of stay (in days), as measured by medical record review 1 year
Secondary Number of patients who returned to work, as assessed by Work Assessment 1 year
Secondary Number of falls, as assessed by Falls questionnaire Participants will answer Yes/No to whether they have had any falls in the preceding 6 months 1 year
Secondary Number of subjects who experienced delirium, as assessed by DOS assessment The Delirium Observation Screening Scale is a 13-item observational scale of verbal and nonverbal behavior. The observations can be done during regular care. The DOS is used to optimize recognition of delirium. 1 year
Secondary Change in quality of life, as assessed by FACT-BMT assessment 50 item assessment. Higher total and domain scores indicate greater quality of life. Baseline, Post-intervention (12 weeks), 1 Year
Secondary Change in quality of life, as assessed by EQ-5D-5L assessment The 5D represents 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Five levels of severity are measured, as indicated by the "5L," ranging from "no problems" to "extreme problems." All scores are converted into a summary index. Baseline, Post-intervention (12 weeks), 1 Year
Secondary Change in quality of life, as assessed by OARS IADL assessment OARS IADL is a 7 item assessment that asks what level of assistance is needed to do 7 different activities of daily living Baseline, Post-intervention (12 weeks), 1 Year
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04889937 - Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population
Not yet recruiting NCT05820126 - Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial Phase 2
Active, not recruiting NCT04509765 - A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT N/A
Not yet recruiting NCT06350994 - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Withdrawn NCT03986086 - MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT02512666 - Non Invasive Optical Imaging of WBC Count N/A
Not yet recruiting NCT02193399 - Physiotherapy in Hematopoietic Stem Cell Transplantation N/A
Withdrawn NCT02207764 - Reiki as a Complementary Therapy: A Pilot Study N/A
Terminated NCT01846429 - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Phase 1
Terminated NCT01215981 - Influenza Vaccine Post Allogeneic Transplant N/A
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Withdrawn NCT04392128 - Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE) Phase 2
Recruiting NCT06102213 - Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation Phase 2
Active, not recruiting NCT04552288 - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Phase 2
Completed NCT03654404 - A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients N/A
Recruiting NCT05384288 - Response to Influenza Vaccination in Pediatric Oncology Patients
Recruiting NCT05084027 - Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT Phase 2